3Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. N Engl J Med, 2001,345: 851-860.
4Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes [J]. N Engl J Med, 2001, 345:870-878.
5The ACE inhibitors diabetic nephropathy trialist group. Should all patients with type 1 diabetes mellitus and microalbuminuria rcceive angiotensin-converting enzymed inhibitorst? A metalanalysis of individual patient data [J]. Ann Intern Med 2001,134:370-379.
6Morgensen CE, Neldsm S, Tiddanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension. microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CLAN) study [J] . BMJ, 2001, 321 : 1440-1444.
7Cohn JN, Tognom G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure [J] . N Engl J Mad, 2001, 345: 1667-1675.
8Doggrell SA, Brown L. The spironolactone renaissance [J].Expret Opin Investig Drugs 2001, 10: 943.
9UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UDPDS 33) [J] . Lancet, 1998, 352: 837-853.
10The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [J]. N Engl J Med, 1993,329: 977-986.
4Johns tone S, Hal Shaw D. Making peace with fluid. Social workers lead cognitive behavioral intervention to reduce health-risk ehavior[J]. Nephrol News Issues, 2003, 17(13) 20-27.
5叶任高.内科学[M]北京:人民卫生出版社,2000155-171.
6王质.血液净化学[M]北京:北京科学技术出版社,2003541.
7Johns tone S,Hal Shaw D. Making peace with fluid.Social -workers lead cognitive behavioral intervention to reduce healthrisk ehavior[J].Nephrology News and Issues,2003,(13):20-27.
